Telix’s half-year report and a new UCLA study landed the same week and pointed the same direction. Telix posted 22% revenue growth and a 146% jump in adjusted EBITDA on a $40 million Regeneron payment, while its lead prostate therapy, TLX591-Tx, cleared an FDA gate to Part 2 of a pivotal U.S. trial. Days earlier, a 112-patient UCLA study found PSMA PET/CT detects recurrence after focal therapy with 85% sensitivity versus 82% for MRI. Commercial strength and imaging evidence are reinforcing each other this quarter.

Telix’s H1 2026 results showed group revenue of $477 million, up 22% year over year, and adjusted EBITDA of $52 million, up 146%, aided by a $40 million payment from its Regeneron radiopharmaceutical collaboration. The company also disclosed that ProstACT Global’s Part 1 lead-in for TLX591-Tx, its lutetium-177 prostate cancer therapy, met safety and dosimetry objectives, and that the FDA confirmed the data are sufficient to advance to Part 2 in the U.S. Telix completed a $600 million convertible bond refinancing and opened a new at-the-market equity facility with Morgan Stanley and William Blair the same day.

A 112-patient UCLA study published August 20 in JNM found gallium-68 PSMA-11 PET/CT detected recurrence after focal therapy with 85% per-patient sensitivity versus 82% for multiparametric MRI, identifying intraprostatic recurrence in 82% of patients, pelvic nodal disease in 15%, and distant metastases in 9%. No standardized criteria for biochemical recurrence after focal therapy exist yet, the authors noted, but the study argues PSMA PET/CT should become the default surveillance tool.

The Phase 3 PSMAddition trial’s full results published August 6 in The Lancet, confirming that adding 177Lu-PSMA-617 to standard hormone therapy cut the risk of progression or death by 28% in more than 1,100 men with PSMA-positive metastatic hormone-sensitive prostate cancer. The data underlie the FDA’s late-July approval of Pluvicto in this earlier setting.

Radiopharm Theranostics said its safety monitoring committee recommended advancing 177Lu-RAD202 to the 180mCi dose level in the Phase 1 HEAT trial, a HER2-targeted radioligand therapy for advanced solid tumors, citing a favorable safety profile through the prior 130mCi cohort.

Defence Therapeutics named Dr. Ryan Simms, a former Fusion Pharmaceuticals R&D leader, Chief Operating Officer and Head of Radiopharmaceutical Programs, adding radioligand-conjugate manufacturing and clinical development expertise as the company builds out its RDC pipeline.

Curium’s acquisition of Lantheus remains subject to shareholder and regulatory approval, with both companies still targeting a first-half-2027 close of the up-to-$8 billion deal.

Radiopharm Theranostics scheduled an FDA End-of-Phase-2 meeting for October 1 to align on a pivotal Phase 3 trial design for RAD101, its brain metastasis imaging agent.